Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss

Diabetes and Metabolism

Volumn 26, Issue 2, 2000, Pages 98-106

  Luyckx, F H ^b   Lefebvre, P J ^a   Scheen, A J ^a  

^a CHU SART TILMAN   (Belgium)

^b NONE

Author keywords

Dyslipidaemia; Gastroplasty; Insulin resistance; Liver; NASH; Obesity; Type 2 diabetes

Indexed keywords

DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; FATTY LIVER; FEMALE; GASTROPLASTY; HEPATITIS; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; HYPERINSULINISM; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER; MALE; OBESITY; SEX FACTORS; WEIGHT LOSS;

EID: 0034068984     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Ludwig J, Viggiano TR, McGill DB, Ott B. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980, 55, 434-438.
2. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology, 1994, 107, 1103-1109.
3. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis, 1999, 19, 221-229.
4. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med, 1997, 126, 137-145.
5. Ludwig J. McGill DB, Lindor KD. Review: Non alcoholic steatohepatitis. J Gastroenterol Hepatol, 1997, 12, 398-403.
6. James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol, 1998, 29, 495-501.
7. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet, 1999, 353, 1634-1636.
8. Day CP, James UFW. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998, 114, 842-845.
9. Telli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural history of non-alcoholic fatty liver: a follow-up study. Hepatology, 1995, 22, 1714-1719.
10. Caldwell SH, Oelsner DH, Lezzoni JC, Hessenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology, 1999, 29, 664-669.
11. Zelman S. The liver in obesity. Arch Intern Med, 1952, 90, 141-156.
12. Braillon A, Capron JP, Hervé MA, Degott C, Quenum C. Liver in obesity. Gut, 1985, 26, 133-139.
13. Clain D, Lefkowitch J. Fatty liver disease in morbid obesity. Gastroenterol Clin North Am, 1987, 16, 239-252.
14. Kern WH, Heger AH, Payne JH. Fatty metamorphosis of the liver in morbid obesity. Arch Pothol, 1973, 96, 342-346.
15. Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obesity, 1995, 19 (Suppl 3), S27-S36.
16. Day CP, James OFW. Hepatic steatosis - innocent bystander or guilty party? Hepatology, 1998, 27, 1463-1466.
17. Kaplan LM. Leptin, obesity, and liver disease. Gastroenterolgy, 1998, 115, 997-1001.
18. George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatothepatitis is associated with increased fibrosis. Gastroenterology, 1998, 114, 311-318.
19. Hotamisligil GH, Spiegelman BM. Tumor necrosis α. A key component of the obesity-diabetes link. Diabetes, 1994, 43, 1271-1278.
20. Alder M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med, 1979, 67, 811-816.
21. Manes JL, Taylor HB, Starkloft GB. Relationship between hepatic morphology and clinical and biochemical findings in morbidly obese patients. J Clin Pathol, 1973, 26, 776-783.
22. Andersen T, Gluud C. Liver morphology in morbid obesity: a literature survey. Int J Obesity, 1984, 8, 97-106.
23. Klain J, Fraser D, Goldstein J et al. Liver histology abnormalities in the morbidly obese. Hepatology, 1989, 10, 873-876.
24. Andersen T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int J Obesity, 1984, 8, 107-115.
25. Wanless IR, Lentz JS. Fatty liver steatosis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology, 1990, 12, 1106-1110.
26. Luyckx FH, Desaive C, Thiry A et al. Liver abnormalities in severely obese subjects: effects of drastic weight loss after gastroplasty. Int J Obesity, 1998, 22, 222-226.
27. Galambos JT, Wills CE. Relationship between 505 paired liver tests and biopsies in 242 obese patients. Gastroenterology, 1978, 74, 1191-1195.
28. Scheen AJ, Paquot N, Letiexhe M, Paolisso G, Castillo MJ, Lefèbvre PJ. Glucose metabolism in obesity: lessons from OGTT, IVGTT, and clamp studies. Int J Obesity, 1995, 19, Suppl 3, S14-S20.
29. Scheen AJ, Lefèbvre PJ. Insulin action in man. Diabetes Metab, 1996, 22, 105-110.
30. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev, 1994, 7, 761-811.
31. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes, 1997, 45, 3-10.
32. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol, 1999, 84 (Suppl 1A), 28J-32J.
33. Scheen AJ, Lefèbvre PJ. Management of the obese diabetic patient. Diabetes Rev, 1999, 7, 77-93.
34. Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis, 1970, 3, 371-407.
35. Stone BG, Van Thiel DH. Diabetes mellitus and the liver. Semin Liver Dis, 1985, 5, 8-28.
36. Zimmerman HJ, MacMurray FG, Rappaport H, Alpert IK. Studies of the liver in diabetes mellitus. II. The significance of fatty metamorphosis and its correlation with insulin insensitivity. J Lab Clin Med, 1950, 36, 922-927.
37. Nagore N, Scheuer PJ. The pathology of diabetic hepatitis. J Pathol, 1998, 156, 155-160.
38. Silverman JF, O'Brien KF, Long S et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol, 1990, 85, 1349-1355.
39. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 1999, 116, 1413-1419.
40. Reaven GM. Role of insulin resistance in human disease. Diabetes, 1988, 37, 1595-607.
41. Oehler G, Bleyl H, Matthes KJ, Hyperinsulinemia in hepatic steatosis. Int J Obesity, 1982, 6 (Suppl 1), 137-144.
42. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab, 1999, 84, 1513-1517.
43. Knobler H, Schattner A, Zhomicki T, et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. Q J Med, 1999, 92, 73-79.
44. Luyckx FH, Scheen AJ, Desaive C, Dewé W, Gielen JE, Lefèbvre PJ. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diabetes Metab, 1998, 24, 355-361.
45. Capron JP, Delamarre J, Dupas JL. Braillon A, Degott C, Quenum C. Fasting in obesity: another cause of liver injury with alcoholic hyaline? Dig Dis Sci, 1982, 27, 265-268.
46. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatology, 1991, 12, 224-229.
47. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand, 1986, 220, 83-88.
48. Keeffe EB, Adesman PW, Stenzel P, Palmer RM. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. Dig Dis Sci, 1987, 32, 441-445.
49. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med, 1970, 282, 829-834.
50. Brown RG, O'Leary JP, Woodyard ER. Hepatic effects of jejunoileal bypass for morbid obesity. Am J Surg, 1974, 127, 53-58.
51. Ames FC, Copeland EM, Leeb DC, Moore DL, Dudrick SJ. Liver dysfunction following small-bowel bypass for obesity. JAMA, 1976, 235, 1249-1252.
52. McFarland RJ, Gazet JC, Pilkington TR. A 13-year review of jejunoileal bypass. Br J Surg, 1985, 72, 81-87.
53. Peters RL. Patterns of hepatic morphology in jejunoileal bypass patients. Am J Clin Nutr, 1977, 30, 53-57.
54. Vyberg M, Ravn V, Andersen B. Pattern of progression in liver injury following jejunoileal bypass for morbid obesity. Liver, 1987, 7, 271-276.
55. Berkovitz D. Metabolic changes associated with obesity before and after weight reduction. JAMA, 1964, 187, 399-403.
56. Rozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis, 1967, 12, 198-207.
57. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology, 1990, 99, 1408-1411.
58. Halverson JD, Zuckerman GR, Koehler RE, et al. Gastric bypass for morbid obesity: A medical-surgical assessment. Ann Surg, 1981, 194, 152-160.
59. Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion, 1990, 47, 208-214.
60. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic stealosis in morbidly obese persons after gastric bypass. Am J Clin Pathol, 1995, 104, 23-31.
61. Letiexhe MR, Scheen AJ, Gérard PL, Desaive C, Lefèbvre PJ. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab, 1995, 89, 393-399.
62. Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diabetes Metab, 1998, 24, 116-123.
63. Luyckx FH, Scheen AJ, Desaive C, Thiry A, Lefèbvre PJ. Parallel reversibility of biological markers of the metabolic syndrome and liver steatosis after gastroplasty-induced weight loss in severe obesity (Letter). J Clin Endocrinol Metab, 1999, 84, 4293.
64. Luyckx FH, Scheen AJ, Lefèbvre PJ. Non-alcoholic steatohepatitis (Letter). Lancet, 1999, 354, 1298-1299.